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Introduction {#sec1}
============

Influenza viruses contain a segmented single-stranded negative-sense RNA genome, which is assembled into viral ribonucleoprotein (vRNP) complexes. In the vRNP, the 5′ and 3′ terminal sequences of the viral RNA (vRNA) associate with the viral RNA-dependent influenza virus RNA polymerase (FluPol) whereas the rest of the vRNA is bound by oligomeric nucleoprotein (NP) ([@bib2], [@bib27]). FluPol replicates and transcribes the vRNA in the context of vRNPs in the nucleus of the host cell. Replication is a two-step, primer-independent process, requiring *de novo* initiation by FluPol, involving the synthesis of a cRNA replicative intermediate from the vRNA template (step 1) and the synthesis of vRNA from the cRNA template (step 2). On the other hand, transcription is a primer-dependent process that results in capped and polyadenylated mRNAs ([@bib31], [@bib38]). Whereas other negative-sense viruses, such as the *Filoviridae* and *Paramyxoviridae*, synthesize their own cap structures ([@bib10]), influenza virus obtains these from cellular transcripts, through a process known as cap snatching ([@bib3], [@bib32]). During cap snatching, FluPol binds host-capped RNAs through its PB2 cap-binding domain, and its PA endonuclease cleaves these to produce 10- to 14-nt-long capped RNA fragments. These are used by FluPol as primers to initiate viral mRNA synthesis. In order to carry out cap snatching, FluPol needs to assume a transcriptional pre-initiation conformation ([@bib38]).

Recently obtained high-resolution structures of FluPol reveal that it consists of a central polymerase core domain made up of PB1, the PA C-terminal (PA C-ter) domain and the N-terminal third of PB2 (PB2 N-ter), and several flexible peripheral appendages, including the N-terminal PA endonuclease and the C-terminal two-thirds of PB2 that encompass the cap-binding domain (CBD), mid-link, 627 and nuclear localization signal (NLS) domains ([@bib16], [@bib30], [@bib34]). The structure of FluPol has been observed in two major distinct conformations. FluPol~A~ and FluPol~B~ bound to vRNA crystallized in a transcription pre-initiation state with the PB2 cap-binding and PA endonuclease domains aligned for cap snatching ([@bib30], [@bib34]). In contrast, the apo form of influenza C virus polymerase (FluPol~C~) and FluPol~B~ bound to the 5′ end of cRNA, crystallized in a transcriptionally inactive conformation, with the PA (P3 in FluPol~C~) endonuclease and C-terminal two thirds of PB2 arranged in a manner incompatible with cap snatching ([@bib16], [@bib39]). Although interaction with vRNA is required for FluPol to assume the transcription pre-initiation conformation, it remains unclear what additional factors regulate the conformational states of FluPol.

In order to cap snatch, FluPol needs to bind host-capped RNAs, which serve as a source of capped RNA primers for viral mRNA synthesis. However, accessing the caps of nascent cellular transcripts presents a challenge, as these are rapidly sequestered by cellular proteins involved in nuclear export and pre-mRNA processing ([@bib9], [@bib21]). FluPol is able to gain preferential access to caps by associating with the initiating form of RNA polymerase II (Pol II) ([@bib6], [@bib13], [@bib23]). This is recognized through a direct and selective interaction with the Ser5-phosphorylated C-terminal domain (CTD) heptad repeat sequence Y~1~S~2~P~3~T~4~pS~5~P~6~S~7~ ([@bib24], [@bib25]), which is the signature for initiating Pol II ([@bib18]). As well as enabling viral transcription, the FluPol-CTD interaction facilitates the suppression of host gene expression by inhibiting Pol II elongation and promoting Pol II degradation ([@bib35], [@bib40]).

In FluPol~A~, there are two sites, both within the PA C-terminal domain, that contribute to CTD binding ([@bib24]). At site 1, Y~1~ of a CTD repeat is bound in a hydrophobic pocket formed by PA residues F440 and F607, whereas the phosphoserine-5 (pS~5~) is accommodated in a positively charged pocket formed by PA K630 and R633. These residues are conserved in FluPol~B~, and unsurprisingly, FluPol~B~ binds CTD in the same conformation at its equivalent site 1. FluPol~A~ site 2 lies in a groove formed by PA β18, β19, and the connecting 550 loop. However, the binding residues of site 2 are not conserved in FluPol~B~, and in this case, the CTD, which is less well ordered, appears instead to extend across the PB2 627 domain ([@bib24]). Neither site 1 nor site 2 residues are conserved in FluPol~C~, raising the question of how FluPol~C~ binds to CTD.

Here, we have crystallized FluPol~C~ bound to a Ser5-phosphorylated Pol II CTD mimic peptide (pS~5~-CTD) consisting of four heptad repeats. We have identified CTD-binding sites, distinct from those observed in FluPol~A~ and FluPol~B~. Furthermore, through a combination of cryoelectron microscopy (cryo-EM) analysis of the vRNA promoter bound FluPol~C~, *in vitro* FluPol~C~ activity assays in the presence of CTD peptides, and cell-based minireplicon assays, we uncover a regulatory mechanism whereby an interaction with the CTD of Pol II is key to the activation of the viral transcriptase.

Results {#sec2}
=======

Structure of the pS~5~-CTD-Bound FluPol~C~ {#sec2.1}
------------------------------------------

We solved the co-crystal structure of FluPol~C~ with a peptide comprising four repeats of the pS~5~-CTD heptad at 4.1 Å resolution ([Table 1](#tbl1){ref-type="table"}). From the difference electron density map, we are able to observe two distinct CTD-binding sites ([Figure 1](#fig1){ref-type="fig"}A). The better defined binding site we observe in FluPol~C~ (site 1) runs from the P3 C-terminal domain (equivalent to the PA C-terminal domain in FluPol~A/B~), close to the tips of helices α24 and α26, toward the P3 linker, between P3 C-terminal domain and PB1 helix α16 in the PB1 palm subdomain ([Figures 1](#fig1){ref-type="fig"}B, 1C, and [S1](#mmc1){ref-type="supplementary-material"}). We were able to model 12 amino acid residues of the CTD with good geometry and consistent with the observed density. The modeled residues encompassed amino acids from three consecutive CTD repeats, T~4a~pS~5a~P~6a~S~7a~-Y~1b~S~2b~P~3b~T~4b~pS~5b~P~6b~S~7b~-Y~1c~ ([Figure 1](#fig1){ref-type="fig"}C). Our modeling was guided by a prominent hydrophobic pocket, which we used as an anchoring point and into which we placed the Y~1b~ of the peptide, in line with previously determined CTD complexes ([Figure 1](#fig1){ref-type="fig"}D) ([@bib17], [@bib24]). Overall, the CTD residues adopt an extended conformation across the binding surface, giving interaction areas of approximately 1,150 Å^2^ with P3 and 500 Å^2^ with PB1. In our model, the phosphate group of pS~5a~ lies in a pocket formed by PB1 residues H461 and R465 and P3 residue P237, whereas the other visible phosphoserine, pS~5b~, points out to the solvent ([Figures 1](#fig1){ref-type="fig"}C and 1E). Both tyrosines, Y~1b~ and Y~1c~, and threonine T~4b~ face FluPol~C~, with Y~1b~ lying close to P3 residues Y241, S661, F663, and PB1 W457; Y~1c~ near to P3 K657; and T~4b~ close to P3 residues N659 and K704 ([Figures 1](#fig1){ref-type="fig"}C and 1D). The second binding site we observe (site 2) is located within a groove formed by P3 β6 and the loop between P3 β11 and β12 ([Figures 1](#fig1){ref-type="fig"}F and [S1](#mmc1){ref-type="supplementary-material"}). Because the electron density here was not of sufficient clarity for confident model building and refinement, we instead indicated the site by tracing a 10-residue poly-alanine chain. There was no visible electron density connecting the two binding sites, although they could potentially be bridged by a peptide encompassing four heptad repeats.Figure 1Structure of FluPol~C~ Bound to Pol II CTD Peptide(A) Surface representation of FluPol~C~ crystal structure with electron density maps shown at CTD-binding sites 1 and 2 (site 1: Sigma-A-weighted *2F*~*o*~*-F*~*c*~, 0.9σ, black mesh; site 2: Sigma-A-weighted *F*~*o*~*-F*~*c*~, 2.6σ, black mesh).(B) Binding site 1 close up with the pS~5~-CTD peptide (yellow) modeled in the Sigma-A-weighted *2F*~*o*~*-F*~*c*~ electron density map (0.9σ).(C) Detailed view of the pS~5~-CTD peptide interaction at site 1 with key amino acids highlighted.(D) Detailed view of the hydrophobic pocket that accommodates Y~1b~.(E) Detailed view of the pocket that accommodates pS~5a~.(F) Binding site 2 close up with poly-alanine chain (yellow) backbone shown in the difference electron density map.(G) Comparison of the Pol II CTD-binding sites on FluPol~C~, FluPol~A~ (PDB: [5M3H](pdb:5M3H){#intref0125}), and FluPol~B~ (PDB: [5M3J](pdb:5M3J){#intref0130}). Site 2 in FluPol~B~ is shown as difference electron density map (Sigma-A-weighted *F*~*o*~*-F*~*c*~, 1.9σ, black mesh).See also [Table 1](#tbl1){ref-type="table"} and [Figures S1](#mmc1){ref-type="supplementary-material"}, [S2](#mmc2){ref-type="supplementary-material"}, and [S3](#mmc1){ref-type="supplementary-material"}.Table 1Crystallographic Data Collection, Phasing, and Refinement StatisticsFluPol~C~-pS~5~-CTD**Diffraction Data**Space groupP 4~3~ 2~1~ 2Cell dimensions (Å)a = 185.7, b = 185.7, c = 597.6α = β = γ = 90Wavelength (Å)0.9795Resolution range of data (last shell; Å)131.38--4.14 (4.21--4.14)Completeness (last shell; %)93.6 (60.6)CC1/2 (%)99.8 (73.3)R~merge~ (last shell; %)20.9 (79.0)I/σI (last shell)7.9 (0.9)Redundancy (last shell)13.5 (2.1)**Refinement**Reflections used in refinement (free)55,611 (2,816)R~work~ (%)26.0R~free~ (%)29.6Number of non-hydrogen atoms35,232Protein35,228Ligand4**Geometry and B factors**RMSD (bonds)0.005RMSD (angles)0.81Ramachandran favored (%)97.37Ramachandran outliers (%)0.23Average B factor146.1Protein146.1Ligand139.5[^4]

The observed CTD binding sites in FluPol~C~ are distinct from all previously observed sites in FluPol~A~ and FluPol~B~ ([@bib24]) ([Figures 1](#fig1){ref-type="fig"}G, [S2](#mmc1){ref-type="supplementary-material"}, and [S3](#mmc1){ref-type="supplementary-material"}). The location of site 1 in FluPol~C~ is different from site 1 in FluPol~A~ and FluPol~B~, and although spatially proximal, it is also distinct from site 2 reported in FluPol~B~. Site 2 in FluPol~B~ runs perpendicular to the interface between the PA~C~ domain and the PB2 627 domain; in our structure, the FluPol is found in a transcriptionally inactive conformation ([@bib16], [@bib39]), where the 627 domain lies level with the endonuclease domain, therefore making this position unavailable ([@bib24]) ([Figure 1](#fig1){ref-type="fig"}G). The second binding site in FluPol~C~ (site 2) is in a position similar to site 2 of the FluPol~A~-CTD complex ([@bib24]). However, the interaction details are likely to be different from FluPol~A~, because the CTD-binding residues of FluPol~A~ site 2 are not conserved in FluPol~C~.

FluPol~C~ Amino Acid Residues Involved in CTD Binding Are Required for Viral Transcription {#sec2.2}
------------------------------------------------------------------------------------------

To address whether the CTD-binding site identified in FluPol~C~ is functionally important, we mutated amino acid residues to alanines in the CTD-binding site 1 ([Figures 1](#fig1){ref-type="fig"}C, [S2](#mmc1){ref-type="supplementary-material"}, and [S3](#mmc1){ref-type="supplementary-material"}) and performed a minireplicon assay. We transfected 293T cells with wild-type or mutant polymerase and nucleoprotein expression plasmids, as well as a plasmid to express a vRNA template, to reconstitute vRNP complexes that produce viral mRNA as well as replication intermediate cRNA and genomic vRNA. The levels of these RNA products were quantified by primer extension analysis ([Figure 2](#fig2){ref-type="fig"}). Only low levels of vRNA, expressed from the transfected plasmid, were observed if the PB1 or P3 subunits were omitted from the transfection, in agreement with previous results ([@bib16]). However, in the presence of a complete wild-type polymerase, we observed mRNA and cRNA, as well as a significant increase in vRNA levels, indicating that the viral polymerase transcribes and replicates the input vRNA. Comparing the RNA levels produced by the wild-type and mutant polymerases, we found that mutations K657A, N659A, S661A, and K704A in P3 specifically inhibited transcription (mRNA levels), but not replication (cRNA and vRNA levels). Furthermore, mutations of PB1 amino acids H461 or R465, which form the charged pocket accommodating pS~5a~ of the CTD, also resulted in specific inhibition of transcription but in no effect or only a small effect on replication. The phenotype of these mutants is fully consistent with the idea that CTD binding is required for viral transcription, as this interaction facilitates access to 5′ caps of nascent Pol II transcripts. Mutations at amino acids P237, Y241, and F663 in P3 and W457 in PB1 affected both transcription and replication, possibly due to their position at the PB1-P3 interface, which might cause them to interfere with heterotrimer assembly. In contrast, mutations K239A, E242A, and R701A in P3 and S458A in PB1 had no major effect on polymerase activity, indicating that these amino acid residues do not contribute critical interactions to CTD binding.Figure 2Effect of Mutations in CTD-Binding Site 1 on FluPol~C~ FunctionThe effect of single-amino-acid mutations in CTD-binding site 1 was analyzed by RNP reconstitution assays. vRNA, mRNA, and cRNA levels were analyzed by primer extension and quantitated by phosphorimage analysis with 5S rRNA as a loading control. RNA levels generated by the wild-type (WT) polymerase were set to 100%. RNP reconstitutions without PB1 (−PB1) or P3 (−P3) served as negative controls. The mean of three independent experiments is shown with error bars representing SD. Asterisks indicate a significant difference from WT (two-tailed one-sample t test) as follows: ^∗^p \< 0.05 and ^∗∗^p \< 0.01.See also [Figures S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}.

PB2 627 and NLS Domains of FluPol~C~ Are Involved in CTD Binding {#sec2.3}
----------------------------------------------------------------

The structure of FluPol~C~ in complex with the Pol II CTD has been obtained in a transcriptionally inactive conformation ([Figure 1](#fig1){ref-type="fig"}A). However, CTD-bound FluPol is proposed to carry out cap snatching and therefore must be present in its transcription pre-initiation state. To investigate the conformational states that FluPol~C~ can assume, we collected a cryo-EM dataset of vRNA promoter-bound FluPol~C~, which resulted in a 9.8-Å reconstruction ([Figure 3](#fig3){ref-type="fig"}). We attempted fitting both the transcription pre-initiation conformation of FluPol~B~ and the transcriptionally inactive apo form of FluPol~C~ into the cryo-EM density map ([Figures 3](#fig3){ref-type="fig"} and [S4](#mmc1){ref-type="supplementary-material"}A). Overall, the transcription pre-initiation conformation of FluPol~B~ produced a significantly better fit, with clear density for the PA endonuclease domain. In agreement with previous observations that the PB2 C-terminal domains are extremely flexible ([@bib16], [@bib34], [@bib39]), the corresponding regions of PB2 in our reconstruction were not resolved, presumably due to dynamic motion. This suggests that, when bound to the vRNA promoter, the polymerase exists as a heterogeneous mixture of conformations, with PB2 undergoing large shifts, which is consistent with what has been observed for vRNA promoter-bound FluPol~B~, where large regions of PB2 electron density are missing in the crystal structure ([@bib34]). Part of the PA C-terminal domain also fits outside the density, but this region correlates with an area of poor resolution, likely due to particles acquiring some preferential orientations in vitreous ice ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B). Our cryo-EM data support a model where vRNA promoter-bound FluPol~C~ is dynamic in solution. Thus, whereas FluPol~C~ can indeed acquire a transcription pre-initiation conformation, this is likely only transient. The presence of promoter vRNA alone therefore appears to be insufficient to stabilize the polymerase in solution in the transcription pre-initiation conformation.Figure 3Cryo-EM Analysis of FluPol~C~ Bound to vRNA PromoterStructure of the vRNA promoter-bound FluPol~B~ in a transcription pre-initiation conformation (PDB: [4WSA](pdb:4WSA){#intref0135}) fit into the cryo-EM density map of FluPol~C~ bound to vRNA promoter.See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

Next, we modeled FluPol~C~ in a transcription pre-initiation conformation, based on the domain arrangement observed in the cryo-EM structure above and the available FluPol~A~ and FluPol~B~ structures ([Figure 4](#fig4){ref-type="fig"}) ([@bib30], [@bib34]). This revealed that, in the transcription pre-initiation conformation, the PB2 627 and NLS domains would lie close to CTD-binding site 1 and could potentially directly interact with the CTD peptide, hence contributing to CTD binding ([Figures 4](#fig4){ref-type="fig"}B and 4C). To address this experimentally, we mutated five surface-exposed amino acid residues of the FluPol~C~ PB2 627 and NLS domains pointing toward the CTD in our model ([Figure 4](#fig4){ref-type="fig"}D). Using vRNP reconstitution assays, as described above, we found that mutations D680A and H710A abolished both transcription and replication, whereas K678A, Q744A, and R748A specifically reduced transcription without having a major effect on vRNA replication ([Figures 5](#fig5){ref-type="fig"} and [S5](#mmc1){ref-type="supplementary-material"}). These results are fully consistent with the 627 and NLS domains of PB2 binding the CTD of Pol II, stabilizing FluPol in the transcription pre-initiation conformation.Figure 4Modeled FluPol~C~ in the Transcription Pre-initiation Conformation Bound to Pol II CTD Peptide(A) Surface representation of pS~5~-CTD-bound FluPol~C~ crystal structure in a transcriptionally inactive conformation with highlighted subunit domain arrangement. pS~5~-CTD is shown in yellow.(B) Surface representation of modeled pS~5~-CTD-bound FluPol~C~ in a transcription pre-initiation conformation with highlighted subunit domain arrangement. The vRNA promoter is shown in black.(C) Detailed view of the PB2 627 and NLS domains packing above the pS~5~-CTD peptide in the transcription pre-initiation conformation of FluPol~C~.(D) Detailed view of the pS~5~-CTD peptide interaction at site 1 in the modeled transcription pre-initiation conformation of FluPol~C~ with key amino acid residues in the PB2 627 and NLS domains highlighted.See also [Figure S5](#mmc1){ref-type="supplementary-material"}.Figure 5Effect of Mutations in the PB2 627 and NLS Domains on FluPol~C~ FunctionThe effect of single-amino-acid mutations in the PB2 627 and NLS domains proximal to CTD-binding site 1 was analyzed by RNP reconstitution assays. vRNA, mRNA, and cRNA levels were analyzed by primer extension and quantitated by phosphorimage analysis with 5S rRNA as a loading control. RNA levels generated by the WT polymerase were set to 100%. RNP reconstitutions without PB2 (−PB2) served as negative controls. The mean of five independent experiments is shown with error bars representing SD. Asterisks indicate a significant difference from WT (two-tailed one-sample t test) as follows: ^∗^p \< 0.05 and ^∗∗^p \< 0.01.See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

Pol II CTD Peptide Enhances FluPol~C~ Transcriptional Activity *In Vitro* {#sec2.4}
-------------------------------------------------------------------------

FluPol is inherently flexible, and in solution, it explores different conformational distributions depending on RNA binding ([@bib16], [@bib39]). However, it remains unclear how the different conformational states are regulated in response to RNA binding and possibly also in response to interactions with host factors. Our data above suggest that binding of FluPol~C~ to the Pol II CTD might stabilize the transcription pre-initiation conformation through interactions between the CTD and the PB2 627 and NLS domains. Therefore, we sought to determine whether the addition of pS~5~-CTD peptide affected the transcriptional activity of FluPol *in vitro*, which is dependent on FluPol, assuming the cap-snatching competent, transcription pre-initiation conformation. We found that the cap-dependent endonuclease activity of vRNA-bound FluPol~C~ was enhanced in the presence of the pS~5~-CTD peptide, resulting in the generation of a capped RNA primer from a 20-nt-long radiolabeled capped RNA ([Figure 6](#fig6){ref-type="fig"}, top panel). In the presence of ribonucleoside triphosphates (rNTPs), the resulting capped RNA was used by FluPol~C~ as a primer to initiate transcription, leading to the production of a capped transcription product ([Figure 6](#fig6){ref-type="fig"}, middle panel). Addition of Ser2-phosphorylated (pS~2~), unphosphorylated (UnP), or scrambled (Scr) peptide had no effect on the cleavage of a 20-nt-long radiolabeled capped RNA, in agreement with pS~5~ being required for the interaction with FluPol ([@bib13], [@bib24], [@bib25]). A specific capped RNA cleavage product was also observed in the absence of vRNA ([Figure 6](#fig6){ref-type="fig"}, top and middle panels), indicating that CTD alone can stabilize the transcription pre-initiation conformation of the polymerase to some extent. However, vRNA binding resulted in increased cleavage, indicating that vRNA binding is also important for the conformational rearrangement as suggested by previous studies ([@bib16], [@bib39]). In order to determine whether only the endonuclease activity or also transcription initiation is enhanced in presence of pS~5~-CTD peptide, we performed an *in vitro* transcription assay in which FluPol~C~ was provided with a radiolabeled 11-nt-long capped RNA primer that can be extended by the polymerase directly without prior cleavage. Addition of pS~5~-CTD also increased transcription initiation ([Figure 6](#fig6){ref-type="fig"}, bottom panel). Therefore, both the cleavage of capped RNA and capped primer-dependent transcription initiation are enhanced when pS~5~-CTD peptide is present. These results are fully consistent with a model in which FluPol~C~ in solution is highly dynamic, flipping between a number of conformations, even when bound to promoter vRNA, but is stabilized in the transcription pre-initiation conformation upon binding to Pol II pS~5~-CTD.Figure 6Effect of Pol II CTD Peptides on FluPol~C~ Endonuclease and Transcriptional Activity*In vitro* endonuclease and cap-dependent transcription initiation assays were performed using purified FluPol~C~ in the presence of pS~5~, pS~2~, un-phosphorylated (UnP), or scrambled (Scr) Pol II CTD peptides. Assays were carried out in the absence or presence of 5′ and 3′ vRNA promoter RNAs. The absence or presence of rNTP substrates is indicated. Top panel: capped RNA cleavage assay is shown; middle panel: capped RNA cleavage and transcription initiation assay are shown; bottom panel: cap-dependent transcription initiation assay is shown. The position of a non-specific cleavage product that partially overlaps with the viral polymerase-specific cleavage products is indicated by a star (^∗^).See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

Discussion {#sec3}
==========

In this study, we identify the Pol II CTD binding site in FluPol~C~ and propose a model for the transcriptional activation of FluPol through binding to host Pol II. Despite the relatively low sequence conservation found between FluPol~A~, FluPol~B~, and FluPol~C~, they are all able to bind pS~5~-CTD, highlighting that binding to Pol II is essential for transcriptional polymerase activity. As all influenza viruses rely on cap snatching to produce mRNA, association with the Pol II CTD provides the viral polymerase with direct access to host-capped RNA. Furthermore, interacting specifically with the pS~5~ form of the CTD ensures FluPol~C~ is present during the brief initial pausing event of Pol II while nascent Pol II transcripts are capped, presumably prior to the capped RNAs being bound by the host nuclear cap-binding complex. Interestingly, the binding sites identified in FluPol~C~ are distinct from those observed in FluPol~A~ and FluPol~B~, illustrating the variety of solutions to CTD binding that the different influenza types have evolved. Site 2 on our FluPol~C~ structure lies at a similar position as the site 2 identified in FluPol~A~, but the lack of conserved amino acids in that region implies that the interaction must involve a different set of residues. The site 1 identified on FluPol~C~ between the P3 C terminus and PB1 is, yet again, entirely distinct despite its somewhat comparable location when compared to the second site observed in FluPol~B~. Our work also shows, in agreement with previous data ([@bib24]), that the FluPol can bind multiple, non-adjacent repeats of the Pol II CTD. The presence of multiple binding sites, which are quite distant from each other, suggests that the Pol II CTD could be partially wrapping around the FluPol, forming multiple, low-affinity interactions but with higher avidity, as is frequently the case in disordered proteins ([@bib11], [@bib45]).

Our structure of FluPol~C~ in complex with a Pol II CTD peptide offers insights into the stabilization of the transcription-competent conformation of the polymerase: site 1 is positioned at an ideal location to interact with the PB2 627 and NLS domains, which, in the transcription pre-initiation conformation, would pack against the CTD peptide. The PB2 627 domain of FluPol~A~ has been attributed a role in host range restriction of influenza viruses, although its role in polymerase function remains still poorly defined ([@bib22], [@bib28]). Our work suggests that the PB2 627 and NLS domains are important for viral transcription by interacting with the Pol II CTD, which contributes to the stabilization of the transcription pre-initiation conformation of the polymerase ([Figure 7](#fig7){ref-type="fig"}). This is consistent with previous observations that the PB2 627 domain is essential for transcription *in vivo*, although it is not required for cap-dependent transcription initiation *in vitro* ([@bib28]). Thus, the PB2 627 domain is not only important for RNA genome replication by mediating the recruitment of a polymerase to nascent viral RNA as proposed previously ([@bib28]), but it also plays a role in transcription, highlighting the multifunctional nature of the influenza virus polymerase. The finding that the CTD interacts with the 627 domain of FluPol~B~ ([@bib24]) suggests that the PB2 627 domain could also play a similar role in stabilizing the transcription pre-initiation FluPol conformation in other influenza types. Indeed, we observed a significant increase in capped-RNA-primed transcriptional activity of FluPol~A~ in the presence of pS~5~ compared to when pS~2,~ UnP, or Scr CTD peptides were added or no CTD peptide was present ([Figure S6](#mmc1){ref-type="supplementary-material"}). These results suggest that the transcriptase conformation of FluPol~A~ is also stabilized upon binding to Pol II CTD. Stabilization of the transcription-competent conformation of FluPol through binding to the CTD of Pol II provides an elegant regulatory mechanism for the activation of the cap-snatching, and thus transcriptional, activity of the influenza virus polymerase and could represent a switch between the transcriptase and replicase functions of FluPol. However, further work will need to be carried out to determine exactly how the polymerases of different influenza virus types in the context of vRNPs interact with the host transcriptional machinery.Figure 7Model for Viral Transcription Activation Induced by Binding to Pol II CTD(A) Prior to association with pS~5~-CTD of Pol II, multiple conformations of vRNP-associated FluPol exist in a dynamic equilibrium. However, most FluPol is likely present in a transcriptionally inactive conformation, in agreement with its low transcriptional activity.(B) FluPol binds to the pS~5~-CTD of Pol II.(C) Binding to the CTD stabilizes FluPol in the transcription-competent conformation as the PB2 627 and NLS domains interact with pS~5~-CTD.(D) In the transcription pre-initiation conformation, with the PB2 cap-binding and PA endonuclease domains reconfigured for cap snatching, FluPol binds the nascent-capped RNA produced by Pol II.(E) Cap snatching occurs, resulting in a short, capped RNA primer, which inserts into the FluPol active site.(F) Transcription initiation takes place, and the capped RNA primer is elongated by FluPol to produce viral mRNA.

In summary, we have identified two Pol II CTD binding sites on FluPol~C~, one in a position similar, but not identical, to site 2 of FluPol~A~ and another in a completely distinct position at the interface of the P3 C-terminal domain and the PB1 palm subdomain. Despite the presence of multiple binding sites, single point mutations at site 1 result in a dramatic impairment of transcription, which highlights the dependency of FluPol on optimal association with the Pol II CTD. This makes the FluPol-Pol II CTD interaction an attractive target for anti-viral small molecule inhibitor development.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Bacterial and Virus Strains**Recombinant baculovirus expressing FluPol~C~ PB1, P3 and PB2-protein A[@bib5], [@bib16]N/ARecombinant baculovirus expressing FluPol~A~ PB1, P3 and PB2-protein A[@bib5], [@bib42]N/A**Chemicals, Peptides, and Recombinant Proteins**AcTEV proteaseThermo Fisher ScientificCat\# 12575015SuperScript IIIThermo Fisher ScientificCat\# 18080093pS~5~-CTD: Biotin-PEG-YSPTS^∗^PSYSPTS^∗^\
PSYSPTS^∗^PSYSPTS^∗^PSCambridge Peptides; [@bib25]N/ApS~2~-CTD: Biotin-PEG-YS^∗^PTSPSYS^∗^PTSPSYS^∗^\
PTSPSYS^∗^PTSPSCambridge Peptides; [@bib25]N/AUnP-CTD: Biotin-PEG-YSPTSPSYSPTSPSYS\
PTSPSYSPTSPSCambridge Peptides; [@bib25]N/AScr-CTD: Biotin-PEG-PSSSTPSSYTPSPSSS\
PTSYSPYYTSPPCambridge Peptides; [@bib25]N/AIgG Sepharose 6 Fast FlowGE HealthcareCat\# 17096901Hi-Load Superdex 200 16/60GE HealthcareCat\# 45-002-490Lipofectamine 2000Thermo Fisher ScientificCat\# 11668027TRI ReagentSigma-AldrichCat\# T9424\[α-^32^P\] GTPPerkinElmerCat\# BLU006H250UCVaccinia capping systemNew England BiolabsCat\# M2080S**Deposited Data**Coordinates of pS~5~-CTD bound FluPol~C~This paperPDB: [6F5O](pdb:6F5O){#intref0010}Cryo-EM map of promoter vRNA bound FluPol~C~This paperEMDB: EMD-4190Imaging data deposited in MendeleyThis paper<https://doi.org/10.17632/tswbw8d2h7.1>**Experimental Models: Cell Lines**HEK293T cellsDunn School Cell BankN/ASf9 insect cellsDunn School Cell BankN/A**Oligonucleotides**vRNA RT primer 5′-CGCAAGGCGACAA\
GGTGCTGA-3′[@bib14]N/Am/cRNA RT primer 5′-ATGTTCTTTACGA\
TGCGATTGGG-3′[@bib14]N/A5S rRNA RT primer 5′-ACCCTGCTTAGCTT\
CCGAGA-3′[@bib15]N/ARNA for capping (20 nt) 5′-ppAAUCUAUAAUAG\
CAUUAUCC-3′Chemgenes; [@bib16]N/ARNA for capping (11 nt) 5′-ppGAAUACUCAAG-3′Chemgenes; [@bib16]N/A5′ FluPol~C~ vRNA promoter RNA 5′-AGCAGUAGCAA\
GGGG-3′Dharmacon; [@bib16]N/A3′ FluPol~C~ vRNA promoter RNA 5′-CCCCUGCUU\
CUGCU-3′Dharmacon; [@bib16]N/A5′ FluPol~A~ vRNA promoter RNA 5′- AGUAGAAAC\
AAGGCC-3′Dharmacon; [@bib14]N/A3′ FluPol~A~ vRNA promoter RNA 5′- GGCCUGCU\
UUUGCU-3′Dharmacon; [@bib14]N/A**Recombinant DNA**pHMG PB1Donated by Nadia Naffakh; [@bib8]N/ApHMG PB2Donated by Nadia Naffakh; [@bib8]N/ApHMG PADonated by Nadia Naffakh; [@bib8]N/ApHMG NPDonated by Nadia Naffakh; [@bib8]N/ApC/PRCATDonated by Nadia Naffakh; [@bib8]N/A**Software and Algorithms**Chimera 1.10.2[@bib29]<https://www.cgl.ucsf.edu/chimera/download.html>ResMap[@bib20]<http://resmap.sourceforge.net/>RELION (VLION)[@bib36]<https://www2.mrc-lmb.cam.ac.uk/relion/index.php/Download_%26_install>EMAN2[@bib37]<http://blake.bcm.edu/emanwiki/EMAN2>Motioncor2[@bib44]<http://msg.ucsf.edu/em/software/motioncor2.html>CryoSPARC[@bib33]<https://v2.cryosparc.com/>GCTF[@bib43]<https://www.mrc-lmb.cam.ac.uk/kzhang/Gctf/>Xia2[@bib41]<https://xia2.github.io/>PHASER[@bib26]<http://www.phaser.cimr.cam.ac.uk/index.php/Phaser_Crystallographic_Software>COOT[@bib12]<https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/>PHENIX[@bib1]<https://www.phenix-online.org/>SWISS-MODEL Oligomer server[@bib4]<https://swissmodel.expasy.org/>Aida Image Analyzer (3.27.001)Elysia RaytestN/A

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Ervin Fodor (<ervin.fodor@path.ox.ac.uk>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### HEK293T Cells {#sec4.3.1}

Human Embryonic Kidney 293 T cells (female cell line) were grown in Dulbecco's Modified Eagle Medium (Sigma-Aldrich) supplemented with 10% fetal calf serum (Sigma-Aldrich). Cells were maintained at 37°C, 5% CO~2~. Cells were trypsinised with TrypLE Express Enzyme (GIBCO).

### Sf9 Insect Cells {#sec4.3.2}

*Spodoptera frugiperda* 9 insect cells (female cell line) were grown in Insect-XPRESS protein-free insect cell medium (Lonza) supplemented with 1x PenStrep (GIBCO). Cell density was maintained between 0.5-2 million cells/ml. Cells were maintained at 27°C, shaking at 110 rpm.

The cell lines used have not been authenticated.

Method Details {#sec4.4}
--------------

### Expression and Purification of FluPol~A~ and FluPol~C~ {#sec4.4.1}

Influenza A/NT/60/68 (H3N2) and C/Johannesburg/1/1966 virus polymerases were expressed using a recombinant baculovirus and purified from insect cells as described ([@bib5], [@bib16], [@bib42]). The heterotrimeric complex was purified from 2 L Sf9 insect cells infected with a baculovirus encoding the three polymerase genes, where the PB2 gene had a C-terminal protein A tag. Cells were grown to a density of 2 million cells/ml and infected with 6 mL V~2~ virus stock per liter of culture. The cells were incubated for 72 h before harvesting by centrifugation at 800 g for 15 min at 4°C. The cell pellet was resuspended in 50 mL lysis buffer (25 mM HEPES pH 7.5, 500 mM NaCl, 10% glycerol, 0.05% OTG, 1x Complete EDTA-free protease inhibitors (Roche)). The cells were lysed by sonication and then centrifuged at 35000 g for 45 min at 4°C. The supernatant was applied to 4 mL equilibrated IgG Sepharose beads and incubated for 3 h. The beads were washed three times with 25 mL wash buffer (25 mM HEPES pH 7.5, 500 mM NaCl, 10% glycerol, 0.05% OTG). For every wash, the beads were incubated for 10 min, rotating at 4°C and then centrifuged at 1000 g for 1 min. The complex was released by incubation with 40 μL TEV protease in 12 mL cleavage buffer (25 mM HEPES pH 7.5, 500 mM NaCl, 10% glycerol, 0.05% OTG, 2.5 mM reduced glutathione) overnight at 4°C. The beads were removed by centrifugation at 4000 g for 5 min. The complex was then further purified by size exclusion chromatography on a Hi-Load Superdex 200 16/60 gel filtration column (GE Healthcare) connected to an Äkta chromatography system (GE Healthcare) at 4°C in gel filtration buffer (25 mM HEPES pH 7.5, 500 mM NaCl, 10 mM MgCl~2~ and 10% (v/v) glycerol). The peak fractions were pooled and concentrated to the desired concentration using an Amicon Ultra centrifugal filter unit (Merck Millipore, NMWL 100 kDa).

### Crystallization and Structure Determination {#sec4.4.2}

For crystallization, a 5 mg/ml solution of FluPol~C~ in 25 mM HEPES:NaOH pH 7.5, 0.5 M NaCl, 10 mM MgCl~2~ and 10% (v/v) glycerol was supplemented with 10% (v/v) pS~5~-CTD peptide (2.7 mM in DMSO) and 0.5 mM TCEP. This was used for sitting-drop vapor-diffusion crystallization experiments at 20°C. Commercial sparse matrix screens were employed to find adequate crystallization conditions including Morpheus (Molecular Dimensions), PEGRx, MembFac, Hampton Natrix Screen and Hampton Crystal Screen Cryo (Hampton Research), Nuc-Pro (Jena Bioscience) and Emerald Wizard I/II (Emerald BioSystems). The best crystal grew from a drop equilibrated against 70% (v/v) Morpheus G2 (Molecular Dimensions) and 7.5% (v/v) glycerol, set up with an initial protein:precipitant ratio of 2:1. This was cryo-protected using 25% (v/v) glycerol in crystallization buffer and then flash cooled in liquid nitrogen. The crystal was exposed at the Diamond Light Source (Didcot, UK), on beamline I04, equipped with a Pilatus 6M detector and using a wavelength of 0.9763 Å.

Reduction of X-ray diffraction data was carried out automatically using Xia2 ([@bib19], [@bib41]). The scaled and merged data were then anisotropy-corrected with the STARANISO server (<http://staraniso.globalphasing.org/>). The structure of FluPol~C~ in complex with the pS~5~-CTD peptide was solved by molecular replacement in PHASER ([@bib26]) utilizing the published apo-structure (PDB: [5D98](pdb:5D98){#intref0090}) as search model. We subjected the structure to multiple rounds of manual building in COOT ([@bib12]) and refinement in PHENIX ([@bib1]) utilizing TLS-parameters, Ramachandran and secondary structure restraints, and two-fold NCS-restraints. The structure was validated using the wwPDB Validation Service (<https://validate-rcsb-1.wwpdb.org/>). Data collection and refinement statistics are shown in [Table 1](#tbl1){ref-type="table"}. Note that the given refinement statistics refer to the anisotropy corrected data.

### Minireplicon Assays Using RNP Reconstitutions and Primer Extension {#sec4.4.3}

Plasmids to express the three FluPol~C~ subunits (pHMG-PB1, pHMG-PB2 and pHMG-P3), nucleoprotein (pHMG-NP) and a plasmid expressing a negative-sense CAT reporter gene flanked by the terminal non-coding sequences of the influenza C/Johannesburg/1/1966 virus NS gene segment (pC/PRCAT) (all kind gifts of Nadia Naffakh, Pasteur Institute Paris), were transfected into HEK293T cells using Lipofectamine 2000 (Invitrogen) ([@bib8]). Total RNA was isolated 30 hr post-transfection by phenol-choroform extraction using Tri Reagent (Invitrogen) and analyzed by reverse transcription with ^32^P-labeled primers 5′-CGCAAGGCGACAAGGTGCTGA-3′ (for detection of vRNA, yielding a 127-nucleotide product) and 5′-ATGTTCTTTACGATGCGATTGGG-3′ (for detection of mRNA and cRNA, yielding 98--102 nucleotide and 89 nucleotide products, respectively) ([@bib14]). A ^32^P-labeled primer 5′-ACCCTGCTTAGCTTCCGAGA-3′ was used to detect 5S rRNA as an internal loading control, for which the expected size of the product was 62 nt ([@bib15]). Input levels of vRNA produced from the pC/PRCAT plasmid were determined by including an RNP reconstitution where one of the plasmids encoding a polymerase subunit was omitted. Products were analyzed by PAGE on 6% acrylamide:bisacrylamide (19:1) gels containing 7 M urea, and detected by autoradiography for generating images for presenting unprocessed data. Quantitation of the data was carried out by exposing the gels directly to phosphor screen imaging plates (Fujifilm), which were scanned on a Fujifilm FLA-5000 scanner. Aida Image Analyzer software (Raytest) was used to determine band intensities.

### *In Vitro* FluPol Activity Assays {#sec4.4.4}

Synthetic RNAs 5′-ppAAUCUAUAAUAGCAUUAUCC-3′ and 5′-ppGAAUACUCAAG-3′ (Chemgenes) were capped and radiolabelled by incubation with \[α-^32^P\] GTP, vaccinia virus capping enzyme (NEB) and 2′-*O*-methyltransferase (NEB), following the manufacturer's instructions. For endonuclease activity assays, 0.5 μL capped RNA was mixed with 1.5 μL purified polymerase (at a final concentration of 142 nM) in 7.5 mM MgCl~2~, 2 mM DTT, and 1 U/μl RNasin (Promega), with or without 0.5 μM 5′ vRNA promoter (5′-AGCAGUAGCAAGGGG-3′) and 0.5 μM 3′ vRNA promoter (5′-CCCCUGCUUCUGCU-3′), in a total reaction volume of 4 μl. For capped RNA primed transcription assays, ATP, UTP, CTP and GTP were added at a final concentration of 0.5 mM each. Pol II CTD peptides ([@bib25]) were added at a final concentration of 1.42 μM where indicated. The reactions were incubated at 30°C for 1 hr. RNA products were analyzed by PAGE on 18% acrylamide:bisacrylamide (19:1) gels containing 7 M urea and detected by autoradiography.

### Cryo-electron Microscopy {#sec4.4.5}

Purified FluPol~C~ was mixed with a 1.2 fold molar excess of 5′ and 3′ promoter vRNAs (5′ vRNA: 5′-AGCAGUAGCAAGGGG-3′; 3′ vRNA: 5′-CCCCUGCUUCUGCU-3′) prior to grid preparation. 3 μL of vRNA promoter-bound FluPol~C~ at 0.5 mg/ml was placed on glow discharged carbon-coated (40 nm film) copper C-flat grids (Protochips) with 2 μm holes and 1.2 μm spacing before blotting for 3 s and flash-freezing in liquid ethane. Grids were prepared using a Vitrobot mark IV (FEI) at 80%--100% humidity. 1822 micrographs were collected on a 300 keV Polara microscope (FEI) fitted with a K2 direct electron detector (Gatan) at magnification 37037x (pixel size 1.35 Å), defocus range −3.5 to −2 μm. A total dose of 46 e^−^/Å^2^ was applied over 22 frames, with a total exposure time of 8.8 s (dose rate 5.23 e^−^/Å^2^/s). Beam-induced drift was corrected using MotionCor2 ([@bib44]) and CTF correction was carried out with GCTF ([@bib43]). Particle picking was carried out in EMAN2 ([@bib37]). All further data processing was carried out using RELION (VLION) ([@bib36]). A total of 48648 particles were extracted of which 15789 remained after 2D classification. Most 2D classes contained particles in two orientations. Particle numbers in different views were therefore balanced to obtain a better distribution of orientations, which resulted in a final set of 9159 particles for 3D reconstruction. 3D reconstruction and refinement were carried out using the apo FluPol~C~ structure (PDB: [5D98](pdb:5D98){#intref0100}) filtered to 40 Å as an initial reference model. Local map resolution was calculated using ResMap ([@bib20]). Fitting of atomic models into the cryo-EM map was carried out using Chimera ([@bib29]).

### Modeling of pS~5~-CTD Bound FluPol~C~ in the Transcription Pre-initiation Conformation {#sec4.4.6}

A model was generated using the SWISS-MODEL Oligomer server (<https://swissmodel.expasy.org/>) ([@bib4]), utilizing the deposited bat FluPol~A~ (PDB: [5M3H](pdb:5M3H){#intref0110}) as a template. The pS~5~-CTD was placed onto the model according to our crystal structure. Finally, the geometry was optimized using the program phenix.geometry_minimization ([@bib1]), yielding good Ramachandran statistics (95.66% favored, 0.68% outliers) and a MolProbity score of 2.0 ([@bib7]).

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Statistical parameters are stated in figure legends and under the appropriate Method details section.

### Minireplicon Assays {#sec4.5.1}

Minireplicon assays ([Figures 2](#fig2){ref-type="fig"} and [5](#fig5){ref-type="fig"}) were performed three (n = 3 for [Figure 2](#fig2){ref-type="fig"}) or five times (n = 5 for [Figure 5](#fig5){ref-type="fig"}). The intensity of the bands corresponding to the different RNA species were quantitated with Aida Image Analyzer software (Raytest). 5S rRNA signal was used as an internal loading control and therefore all band intensities were normalized against the corresponding 5S rRNA signal. Wild-type band intensities were set to represent 100%. The mean of three ([Figure 2](#fig2){ref-type="fig"}) or five ([Figure 5](#fig5){ref-type="fig"}) experiments was used and standard deviations calculated (MS Excel). A two-tailed one-sample t test was employed to determine significant differences between RNA levels produced by wild-type and mutant polymerases. p values below 0.05 (^∗^, p \< 0.05) were considered significant.

### Cryo-EM {#sec4.5.2}

The statistical analyses for map refinement were integral parts of the Relion software package ([@bib36]). Local map resolution ([Figure S4](#mmc1){ref-type="supplementary-material"}) was calculated using ResMap ([@bib20]) with the following parameters: min. resolution 7, max. resolution 15, step resolution: 0.25, voxel size 1.35. Angular distribution of particle orientations was calculated with the cryoSPARC software package ([@bib33]).

### *In Vitro* Polymerase Activity Assays {#sec4.5.3}

*In vitro* polymerase activity assays ([Figure S6](#mmc1){ref-type="supplementary-material"}) were performed three times (n = 3). The intensity of the bands corresponding to the transcription product RNA species were quantitated with Aida Image Analyzer software (Raytest). Band intensities corresponding to the reaction in absence of CTD peptide, in presence of promoter vRNA, were set to represent 100% activity. The mean of three experiments was plotted and standard deviations calculated (MS Excel). A two-tailed one-sample t test was employed to determine significant differences between reactions in presence versus absence of CTD peptides. p values below 0.01 (^∗∗^p \< 0.01) were considered significant.

Data and Software Availability {#sec4.6}
------------------------------

The accession numbers for the data reported in this paper are PDB: [6F5O](pdb:6F5O){#intref0115} and EMDB: EMD-4190.
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